Research Article
No access
Published Online: 31 December 2021

Age, Male Gender, and Social Deprivation Are Associated with a Lower Rate of Insulin Pump Therapy Initiation in Adults with Type 1 Diabetes: A Population-Based Study

Publication: Diabetes Technology & Therapeutics
Volume 23, Issue Number 1

Abstract

Objectives: The objective of this population-based study was to identify factors associated with insulin pump therapy initiation in adults with insulin-requiring diabetes in France in 2015.
Method: People with insulin-requiring diabetes and their characteristics were identified from the national health data system. Factors associated with insulin pump therapy initiation were identified by logistic regression analysis.
Results: The study focused on 614,913 adults with diabetes treated by multiple daily injections before 2015: 4083 of them initiated insulin pump therapy during the year (71% of them had type 1 diabetes, T1D). Factors associated with insulin pump therapy initiation were the number of consultations with an endocrinologist within the past 2 years (2 vs. 0, odds ratio [OR] = 1.5, P < 0.01), the presence of a chronic cardiovascular or neurovascular disease (OR = 1.6 for T1D, OR = 1.3 for type 2 diabetes [T2D], P < 0.01) and treatment with antidepressants/anxiolytics (OR = 1.2 for T1D, OR = 1.4 for T2D, P < 0.01). The other determinants were female gender (OR = 1.5, P < 0.01) and history of hospitalization for acute metabolic complications (OR = 1.14, P < 0.01) in T1D. Factors associated with less insulin pump therapy initiation were age, duration of diabetes, end-stage renal disease, and social deprivation (OR = 0.662, P < 0.01, T1D only).
Conclusion: Predictive factors of insulin pump therapy initiation in people with insulin-requiring diabetes in 2015 in France were globally consistent with clinical practice guidelines. Age, male gender, and social deprivation are still associated with a lower rate of insulin pump therapy initiation in adults with T1D.

Get full access to this article

View all available purchase options and get full access to this article.

References

2. Lassmann-Vague V, Clavel S, Guerci B, et al.: When to treat a diabetic patient using an external insulin pump. Expert consensus. Société francophone du diabète (ex ALFEDIAM) 2009. Diabetes Metab 2010;36:79–85.
3. Pickup JC, Reznik Y, Sutton AJ: Glycemic control during continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: individual patient data meta-analysis and meta-regression of randomized controlled trials. Diabetes Care 2017;40:715–722.
4. Reznik Y, Cohen O, Aronson R, et al.: Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet 2014;384:1265–1272.
5. Ribeiro MEB, Del Roio Liberatore Junior R, Custodio R, Martinelli CE: Continuous insulin therapy versus multiple insulin injections in the management of type 1 diabetes: a longitudinal study. Rev Paul Pediatr (English Edition) 2016;34:86–90.
6. Beato-Víbora P, Chico-Ballesteros A, Giménez M, et al.: A national survey on the efficacy and safety of continuous subcutaneous insulin infusion in patients with type 1 diabetes in Spain. Diabetes Res Clin Pract 2018;137:56–63.
7. Helve E, Koivisto VA, Lehtonen A, et al.: A crossover comparison of continuous insulin infusion and conventional injection treatment of type I diabetes. Acta Med Scand 1987;221:385–393.
8. Pickup JC, Sutton AJ: Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765–774.
9. Chantelau E, Spraul M, Mühlhauser I, et al.: Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for Type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 1989;32:421–426.
10. Vigersky RA, Huang S, Cordero TL, et al.: Improved HbA1c, total daily insulin dose, and treatment satisfaction with insulin pump therapy compared to multiple daily insulin injections in patients with type 2 diabetes irrespective of baseline c-peptide levels. Endocr Pract 2018;24:446–452.
11. The REPOSE Study group. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ 2017;356:j1285.
12. Leinung MC, Thompson S, Luo M, et al.: Use of insulin pump therapy in patients with type 2 diabetes after failure of multiple daily injections. Endocr Pract 2013;19:9–13.
13. Jankovec Z, Hahn M, Grunder S, et al.: Analysis of continuous patient data from the Czech National Register of patients with type 1 and type 2 diabetes using insulin pump therapy. Diabetes Res Clin Pract 2010;87:219–223.
14. Bilic-Curcic I, Vukojevic V, Gradiser M, Berkovic MC: Quality of life in patients treated with insulin pump compared with MDI in Croatia. Diabetes 2018 Jul; 67 (Supplement 1):2278-PUB.
15. Chevreul K, Berg Brigham K, Durand-Zaleski I, Hernández-QuevedoHealth C: France: Health system review. Health Syst Transit 2015;17. www.euro.who.int/en/about-us/partners/observatory/publications/health-system-reviews-hits/full-list-of-country-hits/france-hit-2015
16. Tuppin P, Rudant J, Constantinou P, et al.: Value of a national administrative database to guide public decisions: from the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Revue d'Épidémiol Santé Publique 2017;65(Supplement 4):149–167.
17. Baudot F-O, Aguadé A-S, Barnay T, et al.: Impact of type 2 diabetes on health expenditure: estimation based on individual administrative data. Eur J Health Econ 2019;20:657–668.
18. Bally L, Thabit H, Hovorka R: Finding the right route for insulin delivery—an overview of implantable pump therapy. Expert Opin Drug Deliv 2017;14:1103–1111.
19. Rey G, Rican S, Jougla E: Measuring social inequalities in mortality by cause of death. Ecological approach based on a social deprivation index. Bull Epidemiol Hebd 2011:87–90.
20. French national health insurance. Couverture maladie universelle complémentaire (Complementary universal health coverage); données et statistiques. https://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/donnees-statistiques/couverture-maladie-universelle-cmu.php
21. Andrade L, Rapp T, Sevilla-Dedieu C: Exploring the determinants of endocrinologist visits by patients with diabetes. Eur J Health Econ 2016;17:1173–1184.
22. National Diabetes Insulin Pump Audit. National Diabetes Insulin Pump Audit: what are the outcomes for people using an insulin pump? A summary report of the National Diabetes Insulin Pump Audit for England and Wales 2016–2017. https://www.diabetes.org.uk/resources-s3/2018–12/Insulin_%20Summary_v4.pdf
23. Kampmann U, Madsen LR, Bjerg L, et al.: Prevalence and geographical distribution of insulin pump therapy in the Central Denmark Region and its association with metabolic parameters. Diabetes Res Clin Pract 2018;141:148–155.
24. Jendle JH, Rawshani A, Svensson A-M, et al.: Indications for insulin pump therapy in type 1 diabetes and associations with glycemic control. J Diabetes Sci Technol 2016;10:1027–1033.
25. Kekäläinen P, Juuti M, Walle T, Laatikainen T: Continuous subcutaneous insulin infusion during pregnancy in women with complicated type 1 diabetes is associated with better glycemic control but not with improvement in pregnancy outcomes. Diabetes Technol Ther 2016;18:144–150.
26. Bidmon S, Terlutter R: Gender differences in searching for health information on the internet and the virtual patient-physician relationship in Germany: exploratory results on how men and women differ and why. J Med Internet Res 2015;17:e156.
27. Kalantar-Zadeh K, Derose SF, Nicholas S, et al.: Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus. J Ren Nutr 2019;19:33–37.

Information & Authors

Information

Published In

cover image Diabetes Technology & Therapeutics
Diabetes Technology & Therapeutics
Volume 23Issue Number 1January 2021
Pages: 8 - 19
PubMed: 32522046

History

Published in print: January 2021
Published online: 31 December 2020
Published ahead of production: 10 June 2020

Permissions

Request permissions for this article.

Topics

Data Availability

The data supporting the findings of this study are available from the SNIIRAM/SNDS database. Analyses of the SNIIRAM/SNDS databases have been approved by the French personal data protection agency. Restrictions apply to the availability of these data and may not be publicly available.

Authors

Affiliations

Lise Meunier
CNAM (Caisse Nationale d'Assurance Maladie), French National Health Insurance, Paris, France.
Anne-Sophie Aguadé
CNAM (Caisse Nationale d'Assurance Maladie), French National Health Insurance, Paris, France.
Yann Videau
ERUDITE (Research Team on the Use of Individual Data related to Economic Theory). University of Paris-Est Créteil, Créteil, France.
Dorian Verboux
CNAM (Caisse Nationale d'Assurance Maladie), French National Health Insurance, Paris, France.
Anne Fagot-Campagna
CNAM (Caisse Nationale d'Assurance Maladie), French National Health Insurance, Paris, France.
Christelle Gastaldi-Menager
CNAM (Caisse Nationale d'Assurance Maladie), French National Health Insurance, Paris, France.
Coralie Amadou [email protected]
Department of Diabetes and Endocrinology, University of Paris-Saclay and Sud-Francilien Hospital, Corbeil-Essonnes, France.

Notes

Address correspondence to: Coralie Amadou, MD, MSPH, Department of Diabetes and Endocrinology, University of Paris-Saclay and Sud-Francilien Hospital, 40 Avenue Serge Dassault, Corbeil-Essonnes 91190, France [email protected]

Authors' Contributions

A.-S.A., C.G.-M., A.F.-C., Y.V., and L.M. designed the study. L.M. and A.-S.A. collected the data. L.M., A.-S.A., and D.V. analyzed the data. L.M., A.-S.A., C.G.-M., and Y.V. wrote the first draft. C.A. wrote particularly the introduction and discussion. Finally, all authors wrote, and contributed to the interpretation of the data, revised critically each versions of draft, and globally participated to the whole aspect of the study. C.A. and C.G.-M. take full responsibility for the study as a whole, including the study design, access to data, and the decision to submit and publish the article.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

The project was supported by the French national health insurance.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top